Desperate breast cancer patients get access to promising drug through special program
NCT ID NCT05038631
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This program offers ribociclib, a targeted cancer drug, to patients with serious or life-threatening breast cancer who have no other treatment options and cannot join a clinical trial. Doctors must request the drug for their patients. The goal is to provide potential benefit when standard therapies are exhausted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ribociclib (a targeted cancer drug)
- What this could lead to
- If successful, this program could provide a treatment option for breast cancer patients who have run out of standard therapies.
- What could go wrong
- This is not a clinical trial testing a new treatment; it's an access program. Benefits and risks are not systematically studied, and individual results may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?